Literature DB >> 1599636

Comparison and interaction of low dose felodipine and enalapril in the treatment of essential hypertension in elderly subjects.

T O Morgan1, A Anderson, E Jones.   

Abstract

The antihypertensive effect and tolerance of the combined low doses of felodipine and enalapril (5 + 5 mg daily) were compared with those of either drug at a higher dose level (10 mg daily). Our double-blind, three-way crossover study (balanced Latin square design) involved 36 elderly subjects (mean age 67 +/- 6 years) with essential hypertension. After a 4-week placebo run-in phase the subjects were randomized to the active treatment periods, starting with 5 mg felodipine plus 5 mg enalapril, 5 mg felodipine, or 5 mg enalapril daily for the first 4 weeks. The doses in the felodipine and enalapril periods were then doubled for another 2 weeks. All medication was given once daily in the morning, and blood pressure was measured 24 h after a previous dose. The supine blood pressure for subjects given placebo was 178/101 mm Hg. After 6 weeks' treatment systolic and diastolic supine blood pressures were significantly lower with 5 mg felodipine plus 5 mg enalapril (154/85 mg Hg) than with 10 mg felodipine (159/88 mm Hg) or with 10 mg enalapril (162/91 mm Hg), and the diastolic blood pressure was significantly lower with felodipine than with enalapril. At the end of the felodipine plus enalapril, felodipine, and enalapril treatment periods, 75, 69, and 56% of the subjects, respectively, had a supine diastolic blood pressure 90 mm Hg or less. The combination was tolerated better than either monotherapy. The most commonly reported adverse event was swollen ankles, which occurred in one, nine, and five subjects during felodipine plus enalapril, felodipine, and enalapril treatment, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1599636     DOI: 10.1093/ajh/5.4.238

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  10 in total

Review 1.  Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.

Authors:  Claudio Borghi; Arrigo F G Cicero
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 2.  Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy?

Authors:  D A Sica
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 3.  Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.

Authors:  Domenic A Sica
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 5.  Low dose combination antihypertensive therapy. Additional efficacy without additional adverse effects?

Authors:  A M MacConnachie; D Maclean
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

Review 6.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 7.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

Review 8.  ACE inhibitors. Differential use in elderly patients with hypertension.

Authors:  Z H Israili; W D Hall
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 9.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

10.  Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects.

Authors:  Dai Li; Sumei Xu; Yulu Wang; Dan Li; Xiaomin Li; Jing Pan; Pingsheng Xu
Journal:  Oncotarget       Date:  2017-08-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.